Scilex Holding (SCLX)

• Market cap: $60.8M
• 1 day: 6.71%
• 5 days: 6.34%
• 1 month: 7.83%
• 3 months: -45.06%
• 6 months: -63.6%
• Year to date: -29.49%
• 1 year: -17.96%
• 5 years: -97.35%
• 10 years: -97.32%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Employees: 30